The murine equivalent of the human DNMT1 (DNA [cytosine-5]-methyltransferase 1; Swiss-Prot accession number: P26358) gene was deleted in ES cells via gene targeting [1]. Dnmt1-/-cells possessed dramatically decreased genomic methylation and were viable; however, the mutation caused a homozygous lethal phenotype when introduced into the germline (see Table  of experimental models for DNMT1) [1]. Cre/loxPmediated deletion of Dnmt1 in mice has given rise to several lines of conditional mutants in the nervous system and the immune system [2,3,4]. Mice carrying a hypomorphic Dnmt1 allele showed reduced DNMT1 expression (10% that of wild-type levels) and substantial genome-wide hypomethylation in all tissues [5]. The hypomorphic mutants developed aggressive T-cell lymphomas, supporting a causal role for DNA hypomethylation in tumor formation [5]. When the Dnmt1 hypomorphic allele was introduced to the Apc Min/+ intestinal murine model, a complete suppression of multiple intestinal metaplasia cancerous polyp formation was observed along with reduced CpG island methylation in the intestine, suggesting that Dnmt1 is a genetic suppressor of intestinal polyp formation [6]. Using the same model, the overall inhibition of intestinal tumorigenesis in hypomethylated Apc Min/+ mice was accompanied by microscopic liver tumors; thus, DNA hypomethylation could suppress late stages of intestinal tumorigenesis, but promote early liver lesions [7]. In the human colon cancer cell line HCT116, genetic deletion of DNMT1 did not lead to loss of genomic methylation or reactivation of tumor suppressor genes [8]; however, it has been recently shown that this model was incorrectly targeted, resulting in a catalytically active truncated protein [10,9]. DNMT1 protein has been knocked down via siRNA or oligonucleotide antisense (MG98, see Function and Localization: In disease) degradation of DNMT1 mRNA in HCT116 cells [11]. The effect of depleting DNMT1 from human cancer cell lines using this approach is the basis for MG98 clinical trials. Moreover, the conditional deletion of DNMT1 leads to mitotic catastrophe and ATM/ATR-mediated cell death of HCT116 cells [12]. In HCT116 cells, the conditional deletion model [12] differs from the siRNA knockdown model [11] in that the siRNA is an incomplete knockdown with a less severe phenotype, while the genetic deletion of DNMT1 leads to cell cycle arrest and cell death. It is important to note that one caveat of introducing demethylating drugs is global DNA hypomethylation, leading to the reactivation of previously silenced prometastatic genes [22] in breast cancer cells. Whether demethylating drugs could alter the long-term properties of cancer cells and lead to undesirable outcomes in vivo still remains to be seen.
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Experimental models
The murine equivalent of the human DNMT1 (DNA [cytosine-5]-methyltransferase 1; Swiss-Prot accession number: P26358) gene was deleted in ES cells via gene targeting [1] . Dnmt1-/-cells possessed dramatically decreased genomic methylation and were viable; however, the mutation caused a homozygous lethal phenotype when introduced into the germline (see Table  of experimental models for DNMT1) [1] . Cre/loxPmediated deletion of Dnmt1 in mice has given rise to several lines of conditional mutants in the nervous system and the immune system [2,3,4]. Mice carrying a hypomorphic Dnmt1 allele showed reduced DNMT1 expression (10% that of wild-type levels) and substantial genome-wide hypomethylation in all tissues [5] . The hypomorphic mutants developed aggressive T-cell lymphomas, supporting a causal role for DNA hypomethylation in tumor formation [5] . When the Dnmt1 hypomorphic allele was introduced to the Apc Min/+ intestinal murine model, a complete suppression of multiple intestinal metaplasia cancerous polyp formation was observed along with reduced CpG island methylation in the intestine, suggesting that Dnmt1 is a genetic suppressor of intestinal polyp formation [6] . Using the same model, the overall inhibition of intestinal tumorigenesis in hypomethylated Apc Min/+ mice was accompanied by microscopic liver tumors; thus, DNA hypomethylation could suppress late stages of intestinal tumorigenesis, but promote early liver lesions [7] . In the human colon cancer cell line HCT116, genetic deletion of DNMT1 did not lead to loss of genomic methylation or reactivation of tumor suppressor genes [8] ; however, it has been recently shown that this model was incorrectly targeted, resulting in a catalytically active truncated protein [10, 9] . DNMT1 protein has been knocked down via siRNA or oligonucleotide antisense (MG98, see Function and Localization: In disease) degradation of DNMT1 mRNA in HCT116 cells [11] . The effect of depleting DNMT1 from human cancer cell lines using this approach is the basis for MG98 clinical trials. Moreover, the conditional deletion of DNMT1 leads to mitotic catastrophe and ATM/ATR-mediated cell death of HCT116 cells [12] . In HCT116 cells, the conditional deletion model [12] differs from the siRNA knockdown model [11] in that the siRNA is an incomplete knockdown with a less severe phenotype, while the genetic deletion of DNMT1 leads to cell cycle arrest and cell death.
Drugs and Biologicals
Current status
Drugs DNMT1 (DNA [cytosine-5]-methyltransferase 1) inhibitors, specifically cytidine analogs, are potent anticancer reagents in cell culture models in a variety of human cancers [13] . Hypermethylation of tumor suppressor genes is a common mechanism of gene silencing observed in cancer [14] . In seminal experiments, the inhibition of DNMT1 by either antisense knockdown, cytidine analogs [15, 16] or genetic approaches [17] was shown to inhibit adrenocortical Y1 tumors [16] and intestinal cancer [17] in murine models. These studies, along with testing of cytidine analog inhibitors in a variety of human cancer cell cultures [13] , have paved the way for inhibition of DNA methyltransferases in clinical trials. The following cytidine analogs have been clinically tested for over 25 years: 5-azacytidine (5-aza-CR; Vidaza ® , Pharmion), 5-aza-2'-deoxycytidine (5-aza-CdR; decitabine; Dacogen ® , Supergen and MGI Pharma), and dihydro-5-azacytidine (DHAC). The first two are approved by the FDA for the treatment of myelodysplastic syndrome (MDS), but show little activity in treating solid tumors (see DNA methyltransferase inhibitors in current clinical trials). DHAC is no longer used in clinical trials due to lack of efficacy after Phase II clinical trials treating lung cancer [18] , mesothelioma [19, 20] or melanoma [21] . It is important to note that one caveat of introducing demethylating drugs is global DNA hypomethylation, leading to the reactivation of previously silenced prometastatic genes [22] in breast cancer cells. Whether demethylating drugs could alter the long-term properties of cancer cells and lead to undesirable outcomes in vivo still remains to be seen.
-Aza-CR is activated by uridine-cytidine kinase [23, 24] and is incorporated in place of cytosine into DNA of replicating cells, as well as RNA during transcription [25, 26] . Once incorporated into DNA strands, 5-aza-CR works to inhibit all DNA methyltransferases including DNMT1 by covalently binding to the methyltransferase catalytic domain of the DNA methyltransferase and trapping the enzyme on the DNA strand, thus effectively reducing active DNA methyltransferase and causing genomic demethylation with subsequent rounds of replication [25, 27, 28] . Vidaza ® is the first FDAapproved drug for the treatment of MDS (FDA application 050794) [29] . Unfortunately, there are drawbacks to the usage of 5-Aza-CR to treat cancer in patients. 5-Aza-CR is unstable in aqueous solution and is highly toxic to cells [30, 31] . Even when administered at low dosages, 5-Aza-CR's side-effects include nausea, fatigue, neutropenia, thrombocytopenia, vomiting and fevers [32] . 5-Aza-CR also has a higher preference for RNA incorporation in vivo [32] . 5-Aza-CdR is enzymatically altered by DCK (dCK) and replaces cytosines in the DNA of replicating cells [23] . However, it is not incorporated into RNA and does not alter cellular transcriptional machinery [33] . As 5-azaCdR's mode of action is as a cytosine analog incorporated into DNA during replication, it also traps DNA methyltransferases to DNA via covalent binding to the methyltransferase catalytic domain of the DNA methyltransferase. Cellular toxicity remains a major setback for widespread clinical use. In cell culture systems, 5-aza-CdR induces cell death via P53-mediated apoptosis due to the activation of ATM/ATR cell cycle checkpoint pathways in response to genomic damage [34, 35] 
DNA methyltransferase inhibitors in preclinical trials
Cytidine analogs
Zebularine (1-[β-D-ribofuranosyl]-1,2-dihydropyrimidin -2-one; NSC 309132, Developmental Therapeutics Program, National Cancer Institute, USA) is a chemically stable analog of 5-aza-CR with the same mechanism of action [49] . Zebularine is first processed by uridine-cytidine kinases, which allows for the analog to be incorporated into DNA and RNA by replacing cytosine [50] . Like 5-aza-CR and 5-aza-CdR, DNA methyltransferases are covalently bound to zebularineincorporated DNA strands via the methyltransferase domain, with an apparent preference for DNMT1 [50] . Upon zebularine treatment, genomic demethylation and reactivation of tumor suppressor genes was seen in vitro [49,51,52]. Due to its stability, it can be orally administered and shows less cellular toxicity in animal cancer models [53] . Although zebularine decreases the unwanted toxicity and instability of other cytidine analogs, its mechanism of action is the same and is known to be cytotoxic [31] . Furthermore, to achieve demethylation levels similar to 5-aza-CdR, zebularine must be administered at 100-fold higher concentration in vitro [51] . In a preclinical pharmacokinetic study of zebularine, zebularine metabolism by the liver leads to poor systemic bioavailability in monkey, dog, rat and mouse [54, 55] . For these reasons, there are no current clinical trials using zebularine and research is still at preclinical stages. Non-cytidine analogs Hydralazine (1-hydrazinophthalazine monohydrochloride; apresoline, Novartis Pharmaceuticals), a cardiovascular hypertensive drug, is a weak non-nucleoside inhibitor of DNA methyltransferases through interaction of its nitrogen atoms and the catalytic site of DNA methyltransferases. Hydralazine could cause genomic demethylation and tumor suppressor gene reactivation in breast cancer cell lines [56] . However, when testing suppression of DNA methylation by hydralazine in direct comparison to 5-aza-CR in a variety of cancer cell lines, hydralazine failed to reactivate tumor suppressor genes or reduce DNA methylation levels [44] . Thus, the role of hydralazine as a DNA methyltransferase inhibitor is still controversial.
Center Division of Epigenetics, Heidelberg, Germany], now produced by Sigma Aldrich), a novel small molecule, effectively inhibited DNMT1 activity (IC 50 =115nM) with subsequent demethylation and reactivation of tumor suppressor genes in the human cancer cell lines NALM-6 (acute lymphoblastic leukemia B-cell line) and HCT116 (colon carcinoma cell line) [57] . The inhibitor sterically blocks the catalytic binding site of the human DNMT1 enzyme to induce DNA demethylation [57] . RG108 does not direct demethylation of minor satellite repeats, indicating that RG108 administration will not produce cellular genomic instability and potential mutagenesis [57] .
Patents
Please see Table 1 for a list of relevant DNMT1 patents.
Ligands and antibodies
Examples of DNMT1 antibodies (85 listed on Biocompare; keyword DNMT1) are given in Table 2 .
Therapeutic antibodies
As of 18 November 2008, we are not aware of any reports of immunodepletion or immunosuppressive approaches to target DNMT1 in disease.
Next frontiers
Due to the toxicity of cytidine analogs, researchers are looking into novel small molecule inhibitors directly targeting either the catalytic region of DNMT1 or the target recognition domain (TRD). However, this research is hindered by the lack of known threedimensional structures for full-length human DNMT1 (as of 18 November 2008, we are not aware of a threedimensional structure of human DNMT1 on PDB). Although MG98 directly targets DNMT1 [11], the high doses necessary to knockdown DNMT1 protein produced multiple side-effects outweighing any potential benefits for patients [48] .
Function and Localization
In homeostasis
Function of DNMT1 in gene silencing
Human DNMT1 (DNA [cytosine-5]-methyltransferase 1) is a nuclear protein present in somatic cells and is highly expressed in fetal tissue, moderately expressed in adult brain, heart, thymus and kidney, and weakly expressed in adult skeletal muscle, colon, spleen, liver and lung [58] . When normal mammalian somatic cells are not undergoing mitosis, DNMT1 exhibits a diffusible nucleoplasmic distribution in non-S phase cells and once S phase begins, DNMT1 is targeted to replication foci via N-terminal domains such as the replication foci-directing domain (RFDD) and the PCNA (cyclin)-binding domain (see Figure 1) 
Breast cancer
A non-randomized proof-of-principle study involved the administration of hydralazine in combination with valproate, a histone deacetylase inhibitor, along with chemotherapy to 16 patients. Treatment was well tolerated and appeared to increase the efficacy of patients' chemotherapies, for no patients' symptoms progressed [114] . A Phase I/II clinical trial is ongoing to determine the maximal tolerated dose of hydralazine used in conjunction with chemotherapy in women with breast cancer, with a following Phase II trial to evaluate the efficacy of hydralazine in producing a demethylation effect (NCT00575978; [115]). A Phase I trial is ongoing to study the side-effects and best dose of 5-aza-CdR in treating patients with advanced solid tumors (including breast cancer) that have not responded to previous treatment (NCT00030615; [116]).
Renal cell carcinoma/multiple solid tumors
In preclinical experiments, colon cancer cell lines treated with the antisense inhibitor of DNMT1, RG108, showed subsequent genomic demethylation and reactivation of tumor suppressor genes [11, 45] . MG98 (MGI Pharma and MethylGene), an antisense oligonucleotide, specifically targets and degrades DNMT1 mRNA in cells, leading to over 80% reduction of DNMT1 protein, subsequent genomic demethylation and reactivation of tumor suppressor genes in colon cancer cells in vitro [11, 45] . In tumor xenograft animal experiments, tumor cell proliferation slowed and regression was observed after MG98 administration 
Prostate cancer
In human prostate cancer cell culture models, investigators have shown that DNMT1 activity and transcriptional levels are significantly higher in cancerous cells versus benign prostate cancer cells [117] . In mouse models of prostate cancer, treatment with the DNA methyltransferase inhibitor 5-aza-CdR prevented prostate cancer tumor formation and no occurrence of hypermethylation of the repair gene Mgmt was observed [118] . Furthermore, genetic analysis of induced murine prostate tumors revealed a 2.4% hypermethylation change out of 1200 loci investigated, thus providing evidence for a functional role of DNA methylation in prostate cancer development [119] . A clinical Phase II trial is ongoing to determine what effects 5-aza-CR treatment has in prostate cancer patients (5-aza-CR is only approved by the FDA for MDS) when combined with hormone replacement therapy (NCT00384839; [120]).
Cancer subtypes
There are several ongoing clinical trials to assess the role of DNA methyltransferase inhibitors in a variety of cancer subtypes, due to the FDA approval of 5-aza-CR and 5-aza-CdR for clinical treatment of MDS and AML, and the reactivation of tumor suppressor genes in cell culture models of various human cancers [13] . Currently, 5-aza-CR or 5-aza-CdR, either alone or in combination with other chemotherapy agents, are being tested in the following cancer subtypes: lymphoma 
Hemoglobin disorders: -thalassemia and sickle cell disorder
Sickle cell disorder is linked to a substitution mutation in the HBB (β-globin) gene, causing a deformation of red blood cells [141] . β-thalassemia is an hereditary disease resulting in decreased production of the adult HBB chain, resulting in the premature degradation of red blood cells [142] . In the past, researchers believed that inducing DNA hypomethylation by inhibiting DNA methyltransferases would lead to the reactivation of the fetal hemoglobin gene promoter and potentially compensate for the reduction of the adult HBB. Initial clinical studies showed that 5-aza-CR, a DNA methyltransferase inhibitor, led to a reactivation of fetal hemoglobin in β-thalassemia patients and those with sickle cell disorder [143, 144] ; however, studies were halted due to the mutagenic potential of cytidine analogs in animals [145] . Biochemical studies have shown that DNA methyltransferase-directed methylation of one CpG dinucleotide in the promoter of fetal γ-globin regulates the fetal-to-adult globin switch [146, 147, 148, 149] . The FDA approval of 5-aza-CR and 5-aza-CdR as administered therapeutics to patients with MDS renewed interest in the use of these drugs in hemoglobin disorders (NCT00000623; [150]) [151, 152] . Recently, however, there is a growing body of evidence suggesting that the regulation of globin genes is independent of DNA methylation and the previous reports of reactivation of fetal γ-globin after treatment with demethylating agents is occurring through an unknown mechanism [153, 154] .
Endometriosis
Gene regulation changes have been previously observed in endometrial cells from endometriosis patients, suggesting that alterations in gene expression underlie the disease [155, 156] . Since DNA methylation mediates gene repression, researchers are currently investigating DNA methylation changes in endometrial tissue from patients diagnosed with endometriosis. An increase in DNMT1 in laser-capture micro-dissected endometrial cells of endometriosis patients has been reported; however, it is unclear if the increase in DNMT1 levels correlates with aberrant DNA methylation patterns in diseased cells [157] .
Neurological disorders
While studying gene expression changes in post-mortem brains of schizophrenic patients, DNMT1 mRNA overexpression is observed in inhibitory cortical neurons [158] . Furthermore, tentative evidence suggests that DNMT1 overexpression leads to hypermethylation of RELN (reelin) and DCE1 (GAD67) genes in a subpopulation of inhibitory neurons of schizophrenic, but not bipolar, brains [159,160,161].
Imprinting disorders
Imprinted loci are no longer repressed in Dnmt1 -/-embryos, thus implicating DNMT1 misregulation in imprinting disorders [95] . DNA methylation changes could be involved in Beckwith-Wiedemann syndrome, Silver-Russell syndrome, Prader-Willi syndrome, and Angelman syndrome [162, 163, 164, 165] . Haemophilus haemolyticus demonstrates that the substrate cytosine is completely flipped out of the helix during the modification reaction [173, 174] . Because the catalytic domain of bacterial HhaI DNA methyltransferase is highly homologous to mammalian DNMT1, the crystal structure of bacterial DNA methyltransferase has provided much insight into the possible enzymatic reaction of DNMT1. It is predicted that DNMT1 could also methylate cytosine through a base-flipping mechanism.
Characteristic Structural Features
Domains and motifs
Targeted features
The mechanism of action of cytidine analogs as DNMT1 inhibitors is to incorporate into replicating strands of DNA in place of the endogenous cytosine bases [28, 49] . Once cytidine analogs are incorporated into DNA, they covalently trap DNMT1 at the methyltransferase catalytic domain (amino acids 1139-1616), thus causing depletion of DNA methyltransferase enzyme through subsequent rounds of DNA replication [28, 49] . RG108 is a small molecule that specifically targets and directly binds the DNA methyltransferase catalytic domain (amino acids 1139-1616) [57] . However, all of the above inhibitors target all members of the DNA methyltransferase family, including the de novo methyltransferases DNM3A (DNM3Ta) and DNM3B (DNMT3b) [28, 49, 57] . The antisense oligonucleotide MG98 targets DNMT1 mRNA for degradation, thus creating a transcriptional blockade of DNMT1 protein [11] . However, the largest obstacle in the search for novel DNA methyltransferase inhibitors is the lack of three-dimensional structure modeling of mammalian DNA methyltransferases. In order to develop small molecule inhibitors to different protein domains of DNMT1, the crystal structure of human DNMT1 is first necessary. It is theoretically possible that inhibition of the DNA TRD would also lead to hypomethylation. However, DNA sequence specificity and how DNMT1 targets specific DNA sequence for methylation, in either normal or cancer genomes, is currently unknown. These facts make it difficult to direct inhibition to the TRD of DNMT1. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Lei H., Oh S.P., Okano M., Jüttermann R., Goss K.A., Jaenisch R., Li E. Development 122:3195- 205 (1996) 93. Results of a randomized study of 3 schedules of lowdose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., Faderl S., Bueso-Ramos C., Ravandi F., Estrov Z., Ferrajoli A., Wierda W., Shan J., Davis J., Giles F., Saba H.I., Issa J.P. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. Arce C., Pérez-Plasencia C., González-Fierro A., de la Cruz-Hernández E., Revilla-Vázquez A., Chávez-Blanco A., Trejo-Becerril C., Pérez-Cárdenas E., Taja-Chayeb L., Bargallo E., Villarreal P., Ramírez T., Vela T., Candelaria M., Camargo M.F., Robles E., Dueñas-González A. PLoS ONE 1:e98 (2006) 114. 
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